Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598838 | 0.86 | PLCG1 (0.59) | PLCG1CA2AHRCA9 | |
| SCHEMBL3600873 | 0.81 | PLCG1 (0.61) | PLCG1CA2AHRCMA1CA9 | |
| SCHEMBL10420771 | 0.81 | PLCG1 (0.61) | PLCG1CA2AHRCMA1CA9 | |
| SCHEMBL12060281 | 0.79 | PLCG1 (0.59) | PLCG1CA2CA9 | |
| SCHEMBL14476022 | 0.77 | PLCG1 (0.56) | PLCG1CA2AHRCMA1 | |
| SCHEMBL19307964 | 0.76 | PLCG1 (0.54) | PLCG1CA2CA9 | |
| SCHEMBL13545257 | 0.76 | PLCG1 (0.54) | PLCG1CA2CA9 | |
| SCHEMBL10422692 | 0.76 | PLCG1 (0.54) | PLCG1CA2 | |
| SCHEMBL14476029 | 0.76 | PLCG1 (0.54) | PLCG1CA2CA9 | |
| SCHEMBL13369187 | 0.76 | PLCG1 (0.54) | PLCG1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | PLCG1 4081/4885CA2 887/4885AHR 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.